Pluristem Therapeutics Inc (PSTI)

[Crustacener]

from the beforementioned article:

These preliminary findings support the use of remdesivir for patients who are hospitalized with Covid-19 and require supplemental oxygen therapy. However, given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient. Future strategies should evaluate antiviral agents in combination with other therapeutic approaches or combinations of antiviral agents to continue to improve patient outcomes in Covid-19.

https://www.nejm.org/doi/full/10.1056/NEJMoa2007764